XDx blood test for heart-transplant rejection gets FDA clearance

08/27/2008 | FDAnews · Yahoo!

XDx has received FDA approval to market AlloMap, a blood test designed to help doctors monitor potential organ rejection in heart-transplant patients without the need for repeated biopsies. The test uses blood samples to analyze certain genetic information in white blood cells.

View Full Article in:

FDAnews · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC